Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

Ophthalmic Consultants of Boston

Status and phase: Completed; Phase 1

Conditions: Choroidal Neovascularization

Treatments: Drug: ranibizumab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00395551

FVF 3688 Non-AMD

Details and patient eligibility

About

The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• active choroidal neovascularization

Exclusion criteria

• pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

ranibizumab

Active Comparator group

Description:

ranibizumab 0.5mg intravitreal injection

Treatment:

Drug: ranibizumab